Objective: To investigate the pharmacokinetics and pharmacodynamics of liposomal daunombicin (DaunoXome™) 80 or 100 mg/m2 on days 1, 2 and 3 coadministered with standard or high-dose cytarabine to patients with poor-risk acute leukaemia. Design: Unblinded pharmacokinetic-pharmacodynamic study. Participants: Twenty-three adult patients with acute leukaemia. Methods: Blood, bone marrow and urine samples were collected at appropriate intervals on days 1-6. Total daunombicin and daunombicinol concentrations in plasma, bone marrow, peripheral blood cells and urine were measured by high performance liquid chromatography. Results: Liposomal daunorubicin exhibited a markedly different pharmacokinetic behaviour from the free drug due to a slow distribution of the liposomal moiety into the body. The ratio of area under the concentration-time curve (AUC) for metabolite to parent drug was lower for liposomal daunombicin than for free daunombicin, mainly due to higher concentrations of the parent drug in plasma, whereas daunombicinol exposure was more or less comparable, if not higher. After liposomal daunorubicin at both 80 and 100 mg/m2, total daunorubicin concentrations in leukaemic cells were at least similar to those observed for free daunorubicin, and significant accumulation was also observed in bone marrow blast cells. Nineteen of 23 patients obtained a complete remission, although 13 had P-glycoprotein-overexpressing blast cells. Grade 3-4 mucositis was found only in three patients with very high AUCs for total daunorubicin and daunorubicinol. Conclusions: Liposomal daunorubicin at both 80 and 100 mg/m2 in combination with cytarabine may represent a valid treatment for high-risk acute leukaemia. Liposomal daunorubicin may be helpful in overcoming multidrug resistance, since it shows significant accumulation into tumour target cells, irrespective of P-glycoprotein expression. The tolerability profile suggests that toxicity may be related to exposure to both the parent drug and the metabolite.

Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia

Pea F.;Baccarani M.;
2003

Abstract

Objective: To investigate the pharmacokinetics and pharmacodynamics of liposomal daunombicin (DaunoXome™) 80 or 100 mg/m2 on days 1, 2 and 3 coadministered with standard or high-dose cytarabine to patients with poor-risk acute leukaemia. Design: Unblinded pharmacokinetic-pharmacodynamic study. Participants: Twenty-three adult patients with acute leukaemia. Methods: Blood, bone marrow and urine samples were collected at appropriate intervals on days 1-6. Total daunombicin and daunombicinol concentrations in plasma, bone marrow, peripheral blood cells and urine were measured by high performance liquid chromatography. Results: Liposomal daunorubicin exhibited a markedly different pharmacokinetic behaviour from the free drug due to a slow distribution of the liposomal moiety into the body. The ratio of area under the concentration-time curve (AUC) for metabolite to parent drug was lower for liposomal daunombicin than for free daunombicin, mainly due to higher concentrations of the parent drug in plasma, whereas daunombicinol exposure was more or less comparable, if not higher. After liposomal daunorubicin at both 80 and 100 mg/m2, total daunorubicin concentrations in leukaemic cells were at least similar to those observed for free daunorubicin, and significant accumulation was also observed in bone marrow blast cells. Nineteen of 23 patients obtained a complete remission, although 13 had P-glycoprotein-overexpressing blast cells. Grade 3-4 mucositis was found only in three patients with very high AUCs for total daunorubicin and daunorubicinol. Conclusions: Liposomal daunorubicin at both 80 and 100 mg/m2 in combination with cytarabine may represent a valid treatment for high-risk acute leukaemia. Liposomal daunorubicin may be helpful in overcoming multidrug resistance, since it shows significant accumulation into tumour target cells, irrespective of P-glycoprotein expression. The tolerability profile suggests that toxicity may be related to exposure to both the parent drug and the metabolite.
2003
Pea F.; Russo D.; Michieli M.; Damiani D.; Fanin R.; Michelutti A.; Michelutti T.; Piccolrovazzi S.; Baccarani M.; Furlanut M.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/779688
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact